Sensus Healthcare (SRTS) Stock

The mean of analysts' price targets for Sensus Healthcare (SRTS) points to a 39.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect.

Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and new FDA contracts, including a major deal with Platinum Dermatology, promise recurring revenue and reduced client concentration risk. Despite impressive financial performance, the stock saw minimal movement, presenting a potential 150% upside over the next five years under my assumptions.

Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Signed a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.

Sensus Healthcare, Inc. (SRTS) reachead $6.44 at the closing of the latest trading day, reflecting a +1.58% change compared to its last close.

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $5.90, representing a +1.72% change from its previous close.

Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.